Results
COVID-19 Patients’ mean age was 101.76 ± 27.91 (3 months-18 years) and
75.68 ± 27.34 (1 month-18 years) in the healthy control group. 47.5%
(n=19) of the patients and 60% (n=27) of the control group were male.
No difference was found between the groups in terms of age and gender
distribution (p = 0.061, p=0.248, respectively). The median levels of
vitamin D level were 13.14 (4.19-69.28) in the group of patients with
COVID-19 and 34.81 (3.8-77.42) in the control group. When the COVID-19
patient group and the healthy control group were compared, there were
statistically significantly lower serum phosphorus level
(p<0.001) and vitamin D level (p<0.001) in the COVID
diagnosed patient group. Table 1 depicts the comparison of demographic
and laboratory characteristics between COVID 19 patient group and healty
control subject group.
Patients diagnosed with COVID-19 were divided into 2 groups. Those who
had deficient and insufficient vitamin D levels were determined as Group
1 (n: 29, 72.5%) and normal patients were determined as Group 2 (n: 11,
27.5%). 18 patients in Group 1 were deficient in vitamin D and 11 were
insufficient. When the clinical and laboratory parameters of Group 1 and
Group 2 are compared, at admission, the symptom of fever (34.5%) was
significantly higher in Group 1 than in Group 2 (0%) (p = 0.038). There
were significantly lower levels of vitamin D (p<0.001) and
serum phosphorus (p=0.013) in group 1 than those in group 2. No
significant difference was found between other clinical and laboratory
parameters between the groups. Comparison of demographic, clinical and
laboratory characteristics between COVID 19 diagnosed childrens who had
deficient and insufficient level of vitamin D (group 1) and covid 19
diagnosed childrens who had normal level of vitamin (group 2) is shown
in Table 2.
The distribution of disease severity according to vitamin D levels was
not found significantly different (Table 3).
There was a negative correlation found between fever symptom and vitamin
D level (p = 0.023, Table 4).